Latest News

A selection of recent news and views from Catapult Ventures follows...

Blueberry Therapeutics Appoints Dr. Adrian Howd to Board of Directors

Drug discovery and development company Blueberry Therapeutics announced the appointment of Dr. Adrian Howd to its Board as an independent Non-Executive Director, strengthening its strategic, financial...

Oxford BioTherapeutics Initiates Dose-Escalation Portion of U.S. Phase I Clinical Trial for OBT076 in Patients with Advanced Solid Tumors

Dose-escalation starting at a dose based on results from a European study sponsored by partner, Menarini Ricerche. Phase I program includes two U.S. expansion cohorts: (1) High risk cohort of HER2 negative, Hormone receptor positive (HER2-/HR+) c...

Cytox appoints Ian Gilham as new Chairman of the Board

8th January 2020: Oxford & Manchester, UK. Cytox Ltd, which provides non-invasive, risk assessment and patient stratification tools for Alzheimer's disease and dementia, has appointed Dr Ian Gilham as the new Chairman of the Board. Dr Gil...

UKI2S, Catapult Ventures and Jonathan Milner invest £500k in Gene Modulation Newcomer Pencil Biosciences

11th December, 2019, Alderley Park: UK Innovation & Science Seed Fund (UKI2S), Catapult Ventures’ GM&C Life Sciences Fund and Jonathan Milner are pleased to announced an investment in Pencil Biosciences...

AMRC - Dr Peter Jackson article in Laboratory News

Moving from Push to Pull Nothing less than an entirely new model of drug development is needed if we are to create new antibiotics says Dr Peter Jackson. And it’s something NICE are finally taking seriously as they set about developing a ne...

From our portfolio

Rinicare

Digital Healthcare Technology

Rinicare is an intelligent medical device and software company developing and commercialisin...

viewview our portfolio

Our Team

Emma Johnson

view complete team

Contact us

Binder House
7 Narborough Wood Park
Desford Road
Enderby
Leicester
LE19 4XT

Tel: 0116 238 8200

email